Baader Bank Aktiengesellschaft Takes Position in BridgeBio Pharma, Inc. $BBIO

Baader Bank Aktiengesellschaft acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,525 shares of the company’s stock, valued at approximately $650,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Jones Financial Companies Lllp acquired a new position in BridgeBio Pharma during the 1st quarter worth approximately $35,000. KLP Kapitalforvaltning AS lifted its position in shares of BridgeBio Pharma by 20.1% in the second quarter. KLP Kapitalforvaltning AS now owns 28,035 shares of the company’s stock worth $1,211,000 after purchasing an additional 4,700 shares in the last quarter. Vontobel Holding Ltd. acquired a new position in BridgeBio Pharma during the second quarter worth $424,000. Vanguard Personalized Indexing Management LLC grew its position in BridgeBio Pharma by 5.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 16,178 shares of the company’s stock valued at $699,000 after purchasing an additional 772 shares in the last quarter. Finally, CWM LLC increased its stake in BridgeBio Pharma by 29.8% in the 2nd quarter. CWM LLC now owns 6,830 shares of the company’s stock valued at $295,000 after buying an additional 1,569 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

Insider Buying and Selling at BridgeBio Pharma

In related news, CFO Thomas Trimarchi sold 16,934 shares of the business’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $66.46, for a total value of $1,125,433.64. Following the completion of the sale, the chief financial officer directly owned 382,830 shares in the company, valued at $25,442,881.80. The trade was a 4.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Randal W. Scott sold 10,000 shares of BridgeBio Pharma stock in a transaction on Monday, November 17th. The stock was sold at an average price of $66.65, for a total value of $666,500.00. Following the sale, the director directly owned 11,589 shares of the company’s stock, valued at $772,406.85. This represents a 46.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 260,700 shares of company stock worth $18,157,071 in the last 90 days. Company insiders own 18.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Raymond James Financial restated an “outperform” rating and set a $71.00 price objective (up from $69.00) on shares of BridgeBio Pharma in a research note on Thursday, October 30th. Evercore reissued an “outperform” rating on shares of BridgeBio Pharma in a research report on Monday, October 27th. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of BridgeBio Pharma in a research note on Monday, November 3rd. TD Cowen reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research report on Monday, January 12th. Finally, Cantor Fitzgerald increased their price objective on BridgeBio Pharma from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. Twenty-two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $79.05.

BridgeBio Pharma Stock Up 1.2%

BridgeBio Pharma stock opened at $73.33 on Thursday. The company’s 50-day moving average price is $75.54 and its two-hundred day moving average price is $62.79. The stock has a market cap of $14.13 billion, a P/E ratio of -17.54 and a beta of 1.13. BridgeBio Pharma, Inc. has a twelve month low of $28.33 and a twelve month high of $81.32.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.